{"drugs":["Cis Sulfur Colloid","Technetium Tc 99m Sulfurcolloid","Technetium TC 99m TSC"],"mono":{"0":{"id":"925119-s-0","title":"Generic Names","mono":"Technetium Tc 99m Sulfurcolloid"},"1":{"id":"925119-s-1","title":"Dosing and Indications","sub":{"0":{"id":"925119-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Isotope static scan lymph node, draining a primary tumor in patients with breast cancer or malignant melanoma:<\/b> 3.7 to 37 megabecquerel (0.1 to 1 millicurie) in 0.1 to 1 mL SUBQ<\/li><li><b>Peritoneal venous shunt patency test for Leveen shunt:<\/b> 37 to 111 megabecquerel (1 to 3 millicurie) by INTRAPERITONEAL injection, or 12 to 37 megabecquerel (0.3 to 1 millicurie) in 0.5 mL or less by PERCUTANEOUS TRANSTUBAL INJECTION (efferent limb)<\/li><li><b>Radioisotope study of hematopoietic system, reticuloendothelial cell function in liver, spleen and bone marrow:<\/b> (liver or spleen imaging) 37 to 296 megabecquerels (1 to 8 millicurie) by IV injection<\/li><li><b>Radioisotope study of hematopoietic system, reticuloendothelial cell function in liver, spleen and bone marrow:<\/b> (bone marrow imaging) 111 to 444 megabecquerels (3 to 12 millicurie) by IV injection<\/li><li><b>Radionuclide esophageal study, for esophageal transit or gastroesophageal reflux:<\/b> 5.55 to 11.1 megabecquerel (0.15 to 0.3 millicurie) ORALLY<\/li><li><b>Radionuclide imaging of lung for pulmonary aspiration:<\/b> 11.1 to 18.5 megabecquerel (0.3 to 0.5 millicurie) ORALLY<\/li><\/ul>"},"1":{"id":"925119-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established for uses other than imaging areas of functioning reticuloendothelial cells, gastroesophageal or pulmonary aspiration studies<\/li><li><b>Radioisotope study of hematopoietic system, reticuloendothelial cell function in liver, spleen and bone marrow:<\/b> (liver or spleen imaging, children) 0.56 to 2.78 megabecquerel (0.015 to 0.075 millicurie)\/kg body weight by IV injection<\/li><li><b>Radioisotope study of hematopoietic system, reticuloendothelial cell function in liver, spleen and bone marrow:<\/b> (liver or spleen imaging, newborns) 7.4 to 18.5 megabecquerel (0.2 to 0.5 millicurie) by IV injection<\/li><li><b>Radioisotope study of hematopoietic system, reticuloendothelial cell function in liver, spleen and bone marrow:<\/b> (bone marrow imaging) 1.11 to 5.55 megabecquerel (0.03 to 0.15 millicurie)\/kg body weight by IV injection<\/li><li><b>Radionuclide esophageal study, for esophageal transit or gastroesophageal reflux:<\/b> 3.7 to 11.1 megabecquerel (0.1 to 0.3 millicurie) ORALLY or by NASOGASTRIC tube<\/li><li><b>Radionuclide imaging of lung for pulmonary aspiration:<\/b> 3.7 to 11.1 megabecquerel (0.1 to 0.3 millicurie) ORALLY or by NASOGASTRIC tube<\/li><\/ul>"},"3":{"id":"925119-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Isotope static scan lymph node, draining a primary tumor in patients with breast cancer or malignant melanoma<\/li><li>Peritoneal venous shunt patency test for Leveen shunt<\/li><li>Radioisotope study of hematopoietic system, reticuloendothelial cell function in liver, spleen and bone marrow<\/li><li>Radionuclide esophageal study, for esophageal transit or gastroesophageal reflux<\/li><li>Radionuclide imaging of lung for pulmonary aspiration<\/li><\/ul>"}}},"3":{"id":"925119-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925119-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"925119-s-3-10","title":"Precautions","mono":"<ul><li>anaphylactic reactions (eg, bronchospasm, hypotension, urticaria), including rare fatalities, have been reported;<\/li><li>cancer risk may be increased, especially in children; use smallest dose necessary<\/li><li>high doses (greater than 370 megabecquerels or 10 milliCuries); patients should minimize close contact with infants for 6 or more hours after administration<\/li><li>nursing mothers should express and discard breast milk for at least 6 hours after injection<\/li><li>pregnancy; may cause fetal harm; assess status in women of reproductive potential within 48 hours before administering<\/li><li>radiopharmaceutical; handle with care, maintain adequate shielding of final preparation, and use safety measures to reduce radiation exposure to personnel and patient<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"925119-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>C (AUS)<\/li><\/ul>"},{"id":"925119-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Radioactive compounds that require temporary cessation of breastfeeding.<\/li><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Milk effects are possible.<\/li><\/ul>"}]},"5":{"id":"925119-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension<\/li><li><b>Dermatologic:<\/b>Rash, Urticaria<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiorespiratory arrest<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Seizure<\/li><\/ul>"},"6":{"id":"925119-s-6","title":"Drug Name Info","sub":{"0":{"id":"925119-s-6-17","title":"US Trade Names","mono":"<ul><li>Cis Sulfur Colloid<\/li><li>Technetium TC 99m TSC<\/li><\/ul>"},"2":{"id":"925119-s-6-19","title":"Class","mono":"Diagnostic Agent, Radiopharmaceutical Imaging<br\/>"},"3":{"id":"925119-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"925119-s-7","title":"Mechanism Of Action","mono":"Technetium Tc 99m sulfur colloid is a radioactive pharmaceutical agent for use in diagnostic imaging <br\/>"},"8":{"id":"925119-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"925119-s-8-23","title":"Absorption","mono":"Bioavailability, Oral: none <br\/>"},"2":{"id":"925119-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: 80% to 90%,<\/li><li>Spleen: 5% to 10%<\/li><li>Bone marrow: 5% to 10%<\/li><\/ul>"},"3":{"id":"925119-s-8-26","title":"Excretion","mono":"Fecal: Extensive (oral administration) <br\/>"},"4":{"id":"925119-s-8-27","title":"Elimination Half Life","mono":"2.5 minutes <br\/>"}}},"9":{"id":"925119-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>do not administer directly to patient; proper preparation is required<\/li><li>do not use sodium pertechnetate Tc 99m containing oxidants for reconstitution<\/li><li>do not use sodium pertechnetate Tc 99m containing more than 10 mcg\/mL of aluminum ion for reconstitution due to risk of precipitation that may localize in the lung<\/li><li>wear waterproof gloves during preparation<\/li><li>remove cap from sulfur colloid multidose reaction vial; complete radiation label and affix to vial; place vial in an appropriate lead-capped radiation shield<\/li><li>use a sterile shielded syringe to add 1 to 3 mL sodium pertechnetate Tc 99m to sulfur colloid reaction vial<\/li><li>place a lead cover on vial shield; swirl gently<\/li><li>just prior to use remove cap from Solution A; aseptically withdraw 1.5 mL, inject into reaction vial and swirl<\/li><li>transfer reaction vial from vial shield to a vigorously boiling water bath (shield water bath with 1\/8 to 1\/4 inch lead) deep enough to cover vial contents; leave in water bath 5 minutes<\/li><li>remove reaction vial from water bath, place in lead shield, cool 3 minutes<\/li><li>just before use, remove cap from Solution B; aseptically withdraw 1.5 mL, inject into reaction vial and swirl<\/li><li>record time and date<\/li><li>allow to cool to body temperature before use; maintain adequate shielding at all times<\/li><li>if needed, dilute with sterile sodium chloride injection to achieve dosage within recommended range<\/li><li>withdraw dose with a sterile shielded syringe; use within 6 hours of preparation; minimize time for best results<\/li><li>agitate shielded syringe immediately prior to administration to avoid particle aggregation and non-uniform radioactivity distribution<\/li><li>measure dose by radioactivity calibration system immediately before administration; check radiochemical purity<\/li><li>discard 6 hours after reconstitution<\/li><\/ul>"},"10":{"id":"925119-s-10","title":"Monitoring","mono":"image quality of lymph nodes, peritoneo-venous shunt patency, reticuloendothelial cells in liver, spleen, or bone marrow, esophageal transit, or pulmonary aspirates is indicative of efficacy<br\/>"},"13":{"id":"925119-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause rash, urticaria, anaphylactic shock, hypotension, or a burning sensation at the injection site.<\/li><li>Tell patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed during or around the time of therapy; instruct lactating patients to express and discard milk for at least 6 hours after the injection.<\/li><\/ul>"}}}